Navigation Links
Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
Date:1/31/2008

the 2007 full year. These charges include costs pertaining to the closure of a manufacturing facility owned by Amgen Inc. and used in the production of Enbrel. The closure of the manufacturing facility was completed in the 2007 fourth quarter. The 2006 fourth quarter and full year included productivity initiatives charges of $63.8 million ($48.1 million after-tax or $0.03 per share-diluted) and $218.6 million ($154.5 million after-tax or $0.11 per share-diluted), respectively.

To assist in performing fourth quarter and full year comparisons, a pro forma presentation, which excludes our productivity initiatives and favorable income tax adjustment, is provided under "Results of Operations -- As Adjusted" at the end of this press release.

Segment Information

The following table sets forth worldwide net revenue by reportable segment together with the percentage changes from the comparable period in the prior year:

(UNAUDITED)

Three Months Ended Full Year Ended

12/31/2007 12/31/2007

Net Revenue By

Reportable Segment ($ in millions) Increase ($ in millions) Increase

Pharmaceuticals $4,724 10% $18,622 10%

Consumer Healthcare 787 10% 2,736 8%

Animal Health 253 24% 1,042 11%

Consolidated Total $5,764 10% $22,400 10%

Pharmaceuticals

Worldwide Pharmaceuticals net revenue increased 10% for the 2007 fourth quarter and full year due primarily to higher sales of Enbrel, Prevnar, Nutrition products, Zosyn(R), Protonix and Effexor. The increase in Pharmaceuticals net revenue was offset, in part, by lower sales of Inderal(R) LA due to generic competition. Alliance revenue decreased 13% to $321 million for the 2007 fourth quarter and decreas
'/>"/>

SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
2. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
3. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
4. Wyeth Announces Election of New Principal Corporate Officer
5. Wyeth Declares Preferred Stock Dividend
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
8. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 2014 Two new educational webinars hosted by ... for ALS research and how the pharmaceutical industry can make ... Bucket Challenge: Where Does the ALS Money Go? , Featuring ... 2014, Time: 1:30pm ET, Register to attend , ... Merit Cudkowicz, Julianne Dorn Professor of Neurology at Massachusetts General ...
(Date:11/22/2014)... On November 17th Chicago start-up Briteseed ... Medical Technologies Summit in San Francisco to take first ... among Silicon Valley investors and technology elites as the ... also positions Briteseed to move on to the ... and compete with other elite innovation finalists for a ...
(Date:11/21/2014)... , Todd Martensen ... Mariano Rodríguez es elegid vicepresidente senior de desarrollo empresarial ... en marcha para comenzar de forma rápida la comercialización de ... aprobación en Europa   , KLOX ... los siguientes nombramientos: Todd Martensen ha ...
(Date:11/21/2014)... Palo Alto, Calif. (PRWEB) November 20, 2014 ... (CHI), a nonprofit, public policy research organization representing ... and pharmaceutical firms, and PwC US ... other states in life sciences industry growth. The ... and 2013. The 2015 California Biomedical Industry ...
Breaking Biology Technology:DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4
... Promises to Revolutionize Food Processing, ... ENW) ("EnWave" or "the Company") today announced that ... continuous nutraREV(TM) food dehydration equipment to CAL-SAN Enterprises, ... largest blueberry producers. With this sale, EnWave has ...
... of "In the Zone for UC" Campaign, Centocor Ortho ... Colitis Foundation of America for Each Point Pisani Scores ... Ortho Biotech Inc. announced today a partnership with professional ... colitis (UC) and funding to support continued education and ...
... Colo., March 2 Accera, Inc., ... nervous system (CNS) diseases, today launched Axona(TM) in ... is a first-in-class medical food for the clinical ... mild-to-moderate Alzheimer,s. Dispensed by prescription, it targets the ...
Cached Biology Technology:EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 3EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 4Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 2Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 3Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 4Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 2Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 3Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 4
(Date:11/15/2014)... , Nov. 13, 2014  While we may still ... Doctor McCoy used in "Star Trek" to gain instant access ... designed to work with smartphones and tablets for monitoring and ... the healthcare world. This may seem a tad Orwellian to ... to adopt some of these technological opportunities into their healthcare ...
(Date:11/7/2014)... , Nov. 7, 2014  In conjunction with the ... Police Departments, The Community Foundation of the Verdugos has announced ... DNA JUSTICE PROJECT," a $250,000 initiative to keep the Verdugo ... In its first six months of existence, the Lab has ... support for local law enforcement. "Because our number ...
(Date:11/6/2014)... Insilico Medicine, Inc, a Baltimore-based bioinformatics company focused ... announced a research collaboration with the international leader ... (OTC: CSBR). , "There are many companies utilizing ... Oncology,s TumorGraft technology is unique in a way ... generating vast amounts of valuable data. Our bioinformatic ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... NEW ... uplinks from satellite transmitters fitted on penguins, albatrosses, sea lions, and ... have released the first-ever atlas of the Patagonian Sea a ... ...
... CORVALLIS, Ore. An accidental discovery in a laboratory ... over thousands of years has absorbed the energies of ancient ... the creation of a near-perfect blue pigment. Through ... sought inorganic compounds that could be used to paint things ...
... the Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch ... DNA damage. Dr. Michael Stilmann, Dr. Michael Hinz and ... which detects DNA damage within seconds, activates the transcription ... triggers a survival program, which blocks programmed cell death. ...
Cached Biology News:Penguins and sea lions help produce new atlas 2Accidental discovery produces durable new blue pigment for multiple applications 2How cells tolerate DNA damage -- start signal for cell survival program identified 2How cells tolerate DNA damage -- start signal for cell survival program identified 3
Umbilical cord blood CD14+ Monocytes, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Human peripheral blood neutrophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Human peripheral blood CD14+ monocytes, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Biology Products: